Parainfluenza virus type 3 (PIV-3) causes croup and pneumonia in infants, young children, and immunocompromised individuals (2, 6, 7, 11, 12) and upper respiratory tract illness in older children and adults (8) . It has been estimated that in the United States, PIV-3 infection leads to hospitalization of approximately 1 in 400 children less than 2 years of age and is second only to respiratory syncytial virus (RSV) as a cause of lower respiratory tract (LRT) illness in this population (17) . PIV-3 also causes nosocomial respiratory illness in newborn nurseries, infant and toddler wards, and bone marrow transplant units (9, 13, 15, 16, 19, 23, 24) .
Despite the importance of PIV-3 as a respiratory pathogen, severe LRT illness caused by PIV-3 may be underdiagnosed because sensitive and specific rapid diagnostic tests for PIV-3 are not readily available (23) . Isolation of PIV-3 in cell culture, which remains the standard for diagnosis of infection, may require several weeks; moreover, cultures from the nasopharynx may be negative in patients with LRT disease (23) . Development of a sensitive, specific, and relatively rapid test for PIV-3 might therefore eliminate the need for invasive diagnostic procedures in patients with serious LRT illness (23) , guide the choice of antimicrobial therapy for such patients, and allow hospital personnel to implement adequate infection control measures to prevent the nosocomial transmission of Amplification of viral nucleic acids by PCR has been used for the rapid detection of paramyxoviruses (18, 22, 27) and influenza virus (3) and might be successfully employed to develop a rapid diagnostic assay for PIV-3. We have previously described a reverse transcription (RT)-PCR-sequencing assay for a hypervariable region of the fusion protein gene of PIV-3 which we used to investigate the epidemiology of a PIV-3 outbreak on a pediatric ward (13) . We have also used enzyme immunoassay (EIA) techniques to develop assays for the rapid quantitative detection of amplified nucleic acids in clinical specimens (PCR-EIA) (5, 25 (1) . In this study, nasopharyngeal swab specimens were obtained daily from each subject from day 0 (the day of inoculation) through day 11; a subset of these specimens was available for testing by RT-PCR-EIA. Two of the children shed wild-type PIV-2 during the study. Six children had been enrolled in trials of other respiratory virus vaccines, but wild-type PIV-3 grew from the nasal washes obtained from each child (by previously described methods [21] ). All of the specimens from these six children were available for testing by RT-PCR-EIA. In all instances, informed, witnessed, written consent had been obtained from the parents prior to participation in vaccine trials.
Quantitative data on viral shedding were generated for specimens from cp-18 JS strain PIV-3 vaccine study participants which were tested by RT-PCR-EIA. (1) . For purposes of calculation, specimens that were culture negative were assigned a titer of 100°5 PFU/ml. Specimens that grew PIV-3 in the initial culture but which were culture negative upon titration were assigned a titer of 100°75 PFU/ml so that they could be distinguished from true culture-negative specimens. Phenotypic analysis to distinguish wild-type PIV-3 from vaccine strain PIV-3 was performed in the study of the live attenuated PIV-3 vaccine (1) .
RT-PCR-EIA. For RT-PCR, specimens were diluted 1:10 in distilled water, extracted, and amplified by previously described methods (13 York, N.Y.). The probe was purified as previously described (5, 26) and stored at -70°C. The nonisotopic solution hybridization reaction and EIA for detection of amplified sequences were also performed as previously described (5, 26) . Positive and negative control samples were included in each assay. The positive PCR control was an RT preparation of PIV-3 stock that had been PCR positive in previous assays. The positive EIA control was a titration of PCR product from a PIV-3 stock preparation that was amplified in quantity and stored frozen at -70°C. In studies of tissue culture-grown virus, supernatant from uninfected Rhesus monkey kidney cells was included in each RT-PCR-EIA as a negative control. In studies using nasal wash or nasal swab specimens, an aliquot of the pooled culture-negative nasal washes described above was included in each RT-PCR-EIA as a negative control. All samples were run in duplicate. A sample was considered to be positive if it generated a fluorescence activity three standard deviations greater than the mean activity generated by the negative control samples included in the assay. Positive samples were further quantified by subtracting the mean fluorescence of the negative controls from the mean fluorescence of the sample. All data are expressed in fluorescence units, defined as mean fluorescence of the sample minus mean fluorescence of the negative control.
Statistical analysis. The correlation between viral titer and specific activity in PCR-EIA was calculated by the method of Spearman, as described by Snedecor and Cochran (20) . Table 1 ). The RT-PCR-EIA also appeared to be specific for PIV-3: all but one of the day 0 specimens were RT-PCR-EIA negative (see below), and all of the specimens which were culture positive for PIV-2 were RT-PCR-EIA negative.
As mentioned above, the day 0 specimen from one study subject (no. 17) was culture negative but RT-PCR-EIA positive. Specimens from this child, who received the live attenuated cp-18 JS strain PIV-3 vaccine, were culture negative for PIV-3 but RT-PCR-EIA positive on days 0 and 1 (438 and 57 fluorescence units, respectively). The child also had an eightfold rise in serum hemagglutinating antibody to PIV-3 in paired serum specimens obtained on days 0 and 28 of the study. The child's sister, who was a placebo recipient, shed wild-type PIV-3 on day 6 of the study. These data suggest that subject 17 was naturally infected with wild-type PIV-3 prior to the onset of the vaccine trial and that these RT-PCR-EIA-positive, culture-negative specimens represent true positives.
Correlation between viral titer and RT-PCR-EIA specific activity. The Spearman rank correlation coefficient (ru, corrected for ties) for viral titer and specific activity was 0.684 and was highly significant (P = 0.0001). DISCUSSION This study documents the sensitivity and specificity of our RT-PCR-EIA for the detection of PIV-3 in cell culture-grown virus stocks and, more importantly, in respiratory tract samples obtained from children infected with PIV-3. Our assay, which amplified a highly conserved region of the HN gene (4), was able to detect seven strains of PIV-3 isolated over 26 years but did not detect other types of PIV (either in stock specimens or in respiratory tract samples), paramyxoviruses other than PIV, or influenza viruses. As measured by serial titration of a single strain of PIV-3, the RT-PCR-EIA was at least as sensitive as cell culture, the limits of detection being approximately 1 PFU/ml. This finding was confirmed in the experiments using volunteer specimens, in which 40 specimens were culture positive and RT-PCR-EIA positive, 8 specimens were RT-PCR-EIA positive but culture negative, and 11 specimens were culture positive but RT-PCR-EIA negative (although none of these last specimens were culture positive after a single cycle of freeze-thawing, suggesting that virus was present at a very low titer). The sensitivity of this assay might be enhanced 10-fold by using undiluted nasal wash specimens. We diluted specimens for this study because of the limited volumes available and concern about the presence of PCR inhibitors in patient samples (25) . However, our titration experiments, in which we serially diluted virus into undiluted pooled nasal washes, suggest that our PCR is not inhibited by nasal secretions.
If these preliminary observations are confirmed in subsequent studies, the PIV-3 RT-PCR-EIA might be a particularly useful diagnostic tool for immunocompromised patients with PIV-3 LRT disease. Rapid diagnosis of PIV-3 infection in these patients might lessen the use of broad-spectrum antibiotics, or, in certain patients, promote the timely use of ribavirin, which has been reported anecdotally to ameliorate PIV-3 disease (10, 14) . Rapid diagnosis would also promote the use of appropriate infection control measures (patient cohorting and isolation procedures) to control nosocomial transmission of PIV-3 in these settings. Because nasopharyngeal viral cultures are often not obtained from immunocompromised patients at the time of the upper respiratory tract illness and may be negative (or require weeks in culture to become positive) at the time of LRT disease (23), an RT-PCR-EIA for PIV-3 which can detect viral RNA in the nasopharynx at the time of LRT disease might, in selected patients, also eliminate the need for invasive diagnostic procedures. Alternatively, RT-PCR-EIA of LRT specimens from those patients who require bronchoscopy or open lung biopsy would permit more rapid diagnosis of PIV-3 infection than typically occurs with standard culture techniques (2 days with the RT-PCR-EIA versus a median of 9 days with standard techniques [23] ). As nucleic acid amplification assays have been described for other respiratory viruses (3, 18) , this assay might ultimately be used as part of a panel to detect the presence of respiratory viral RNA in high-risk individuals. Thus, the use of this RT-PCR-EIA for rapid diagnosis of PIV-3 infection in hospital settings could benefit patients with PIV-3 infection and their contacts.
